thiosulfates has been researched along with Ovarian Neoplasms in 29 studies
Thiosulfates: Inorganic salts of thiosulfuric acid possessing the general formula R2S2O3.
thiosulfate(2-) : A divalent inorganic anion obtained by removal of both protons from thiosulfuric acid.
Ovarian Neoplasms: Tumors or cancer of the OVARY. These neoplasms can be benign or malignant. They are classified according to the tissue of origin, such as the surface EPITHELIUM, the stromal endocrine cells, and the totipotent GERM CELLS.
| Excerpt | Relevance | Reference |
|---|---|---|
| "We conducted a phase II trial of intraperitoneal (IP) cisplatin (DDP) and etoposide (VP-16) in stage III and IV newly diagnosed ovarian carcinoma patients with residual disease of any size." | 3.68 | A phase II trial of intraperitoneal cisplatin and etoposide for primary treatment of ovarian epithelial cancer. ( Goel, R; Horton, MC; Howell, SB; Kim, S; Kirmani, S; Lucas, WE; McVey, L; Morris, J; Weiss, RJ; Zimm, S, 1990) |
| "As in many ovarian cancer patients the disease remains confined to the peritoneal cavity, intraperitoneal (i." | 2.68 | Experience with intraperitoneal cisplatin and etoposide and i.v. sodium thiosulphate protection in ovarian cancer patients with either pathologically complete response or minimal residual disease. ( Burger, CW; Hoekman, K; van Rijswijk, RE; Verheijen, RH; Vermorken, JB, 1997) |
| "We conclude that the French ovarian cancer protocol may represent a significant advance and that glucose potentiation may be more widely applicable as an adjunct to cancer chemotherapy." | 2.67 | Glucose effects in an ovarian cancer protocol of exceptional activity. ( Lin, JY; Scheim, DE, 1993) |
| "Sodium thiosulfate was given as an intravenous antidote to cisplatin." | 2.67 | Intraperitoneal high-dose cisplatin and etoposide with systemic thiosulfate protection in second-line treatment of advanced ovarian cancer. ( Malmström, H; Rasmussen, S; Simonsen, E, 1993) |
| "Ovarian carcinoma demonstrates a steep dose-response curve for cisplatin, but even very small levels of acquired resistance at the cellular level are sufficient to block the efficacy of intravenous (IV) cisplatin." | 2.38 | Intraperitoneal cisplatin-based chemotherapy for ovarian carcinoma. ( Braly, P; Howell, SB; Kim, S; Kirmani, S; McClay, EF; Plaxe, S, 1991) |
| "These patients included those with ovarian cancer (3 cases), metastatic ovarian cancer (1 case), and endometrial cancer (1 case)." | 1.27 | [Treatment of gynecological cancer with cis-platinum]. ( Mano, T; Miyake, T; Nakamura, Y; Saito, T; Takeshima, N; Tomimatsu, T, 1987) |
| "Treatment of patients with advanced ovarian cancer who have failure of first-line chemotherapy is rarely effective." | 1.27 | Intraperitoneal chemotherapy for advanced ovarian cancer. ( Howell, SB; Lucas, WE; Markman, M, 1985) |
| "Sodium thiosulfate was shown to protect renal function, as well as lessen hematologic complications of cisplatin therapy." | 1.27 | Experimental and clinical results with intraperitoneal cisplatin. ( Aartsen, E; Dubbelman, R; Franklin, H; McVie, JG; ten Bokkel Huinink, WW, 1985) |
| "Sodium thiosulfate has been shown experimentally to protect against cisplatin-induced renal insufficiency by inactivating the nephrotoxic as well as cytotoxic properties of the agent." | 1.27 | Nephrotoxicity of high-dose intracavitary cisplatin with intravenous thiosulfate protection. ( Cleary, S; Howell, SB; Markman, M, 1985) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 15 (51.72) | 18.7374 |
| 1990's | 13 (44.83) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (3.45) | 2.80 |
| Authors | Studies |
|---|---|
| Senguttuvan, RN | 1 |
| Santiago, NL | 1 |
| Han, ES | 1 |
| Lee, B | 1 |
| Lee, S | 1 |
| Lin, WC | 1 |
| Kebria, M | 1 |
| Hakim, A | 1 |
| Lin, JF | 1 |
| Wakabayashi, MT | 1 |
| Ruel, N | 1 |
| Tinsley, R | 1 |
| Eng, M | 1 |
| Stewart, DB | 1 |
| Wang, EW | 1 |
| Paz, BI | 1 |
| Wu, X | 1 |
| Cho, H | 1 |
| Liang, WS | 1 |
| Rodriguez-Rodriguez, L | 1 |
| Cristea, MC | 1 |
| Raoof, M | 1 |
| Dellinger, TH | 1 |
| Hatae, M | 2 |
| Tezuka, H | 1 |
| Ushiki, N | 1 |
| Ezono, Y | 1 |
| Igyuin, H | 1 |
| Terahara, M | 1 |
| Hokanishi, H | 1 |
| Howell, SB | 7 |
| Pfeifle, CE | 2 |
| Wung, WE | 1 |
| Olshen, RA | 1 |
| de Jong, RS | 1 |
| Willemse, PH | 1 |
| Boonstra, H | 1 |
| de Vries, EG | 1 |
| van der Graaf, WT | 1 |
| Sleijfer, DT | 1 |
| van der Zee, AG | 1 |
| Mulder, NH | 1 |
| Scheim, DE | 1 |
| Lin, JY | 1 |
| Ben-Baruch, G | 3 |
| Menczer, J | 3 |
| Feldman, B | 1 |
| Rizel, S | 3 |
| Brenner, H | 3 |
| Guastalla, JP | 1 |
| Vermorken, JB | 2 |
| Wils, JA | 1 |
| George, M | 1 |
| Scotto, V | 1 |
| Nooij, M | 1 |
| ten Bokkel Huinnink, WW | 1 |
| Dalesio, O | 1 |
| Renard, J | 1 |
| Malmström, H | 1 |
| Rasmussen, S | 1 |
| Simonsen, E | 1 |
| van Rijswijk, RE | 1 |
| Hoekman, K | 1 |
| Burger, CW | 1 |
| Verheijen, RH | 1 |
| Takizawa, K | 3 |
| Harada, M | 2 |
| Fujimaru, J | 2 |
| Matsushiro, N | 1 |
| Shima, Y | 2 |
| Andoh, I | 1 |
| Satoh, M | 1 |
| Yokoo, I | 2 |
| Iguchi, T | 3 |
| Hirabayashi, K | 1 |
| Kirmani, S | 2 |
| McClay, EF | 1 |
| Kim, S | 2 |
| Braly, P | 1 |
| Plaxe, S | 1 |
| Abe, R | 1 |
| Akiyoshi, T | 1 |
| Baba, T | 1 |
| Lucas, WE | 2 |
| Zimm, S | 1 |
| Goel, R | 1 |
| Horton, MC | 1 |
| McVey, L | 1 |
| Morris, J | 1 |
| Weiss, RJ | 1 |
| Ozaki, I | 1 |
| Sato, M | 2 |
| Takeda, Y | 2 |
| Canal, P | 1 |
| de Forni, M | 1 |
| Chatelut, E | 1 |
| Chevreau, C | 1 |
| Johnson, NP | 1 |
| Houin, G | 1 |
| Bugat, R | 1 |
| Markman, M | 4 |
| Cleary, S | 3 |
| Ino, Y | 1 |
| Isono, T | 1 |
| Maruyama, M | 1 |
| Noda, T | 1 |
| Kiyozuka, Y | 1 |
| Oku, M | 1 |
| Ninomiya, Y | 1 |
| Ibaraki, T | 1 |
| Katoh, Y | 1 |
| Itani, Y | 1 |
| Okamura, Y | 1 |
| Beppu, K | 1 |
| Tateyama, I | 1 |
| Kamitani, N | 1 |
| Tominaga, T | 1 |
| Mori, T | 1 |
| Mano, T | 1 |
| Takeshima, N | 1 |
| Nakamura, Y | 1 |
| Tomimatsu, T | 1 |
| Saito, T | 1 |
| Miyake, T | 1 |
| Miyahara, K | 1 |
| Miyoshi, T | 1 |
| Kobayashi, H | 1 |
| Hamai, J | 1 |
| Tomoo, Y | 1 |
| Yamada, T | 1 |
| Nishimura, H | 1 |
| Yakushiji, M | 1 |
| Kato, T | 1 |
| ten Bokkel Huinink, WW | 1 |
| Dubbelman, R | 1 |
| Aartsen, E | 1 |
| Franklin, H | 1 |
| McVie, JG | 1 |
| Ozols, R | 1 |
1 review available for thiosulfates and Ovarian Neoplasms
| Article | Year |
|---|---|
Intraperitoneal cisplatin-based chemotherapy for ovarian carcinoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Antioxidants; Cisplatin; Etoposide; Female; Humans; | 1991 |
6 trials available for thiosulfates and Ovarian Neoplasms
| Article | Year |
|---|---|
Phase II study of intraperitoneal cisplatin plus systemic etoposide as second-line treatment in patients with small volume residual ovarian cancer.
Topics: Administration, Topical; Adult; Aged; Antioxidants; Cisplatin; Disease-Free Survival; Drug Therapy, | 1995 |
Glucose effects in an ovarian cancer protocol of exceptional activity.
Topics: Actuarial Analysis; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cisplatin; Cytarabine | 1993 |
Phase II trial for intraperitoneal cisplatin plus intravenous sodium thiosulphate in advanced ovarian carcinoma patients with minimal residual disease after cisplatin-based chemotherapy--a phase II study of the EORTC Gynaecological Cancer Cooperative Grou
Topics: Aged; Catheterization, Peripheral; Cisplatin; Female; Humans; Infusions, Parenteral; Kidney Diseases | 1994 |
Intraperitoneal high-dose cisplatin and etoposide with systemic thiosulfate protection in second-line treatment of advanced ovarian cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Etoposide; Female; Humans; I | 1993 |
Experience with intraperitoneal cisplatin and etoposide and i.v. sodium thiosulphate protection in ovarian cancer patients with either pathologically complete response or minimal residual disease.
Topics: Adult; Aged; Antidotes; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Prot | 1997 |
[The clinical and pharmacokinetic evaluation of two-route chemotherapy with cisplatin and sodium thiosulfate in combination with angiotensin II].
Topics: Angiotensin II; Blood Pressure; Cisplatin; Drug Therapy, Combination; Female; Humans; Ovarian Neopla | 1992 |
22 other studies available for thiosulfates and Ovarian Neoplasms
| Article | Year |
|---|---|
ASO Visual Abstract: Impact of Sodium Thiosulfate on Prevention of Nephrotoxicities in HIPEC: An Ancillary Evaluation of Cisplatin-Induced Toxicities in Ovarian Cancer.
Topics: Cisplatin; Cytoreduction Surgical Procedures; Female; Humans; Hyperthermia, Induced; Hyperthermic In | 2024 |
[Intraperitoneal and intrapleural two channel chemotherapy by cisplatinum (DDP) and sodium thiosulfate for the treatment of ovarian cancer].
Topics: Adenocarcinoma; Adult; Carcinoma, Squamous Cell; Cisplatin; Cystadenocarcinoma; Drug Therapy, Combin | 1984 |
Intraperitoneal cis-diamminedichloroplatinum with systemic thiosulfate protection.
Topics: Adult; Cell Division; Cell Line; Cisplatin; Dose-Response Relationship, Drug; Drug Evaluation; Drug | 1983 |
Intraperitoneal cisplatin chemotherapy versus abdominopelvic irradiation in ovarian carcinoma patients after second look laparotomy. A reassessment based on mature data.
Topics: Abdomen; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Cisplatin; Combined Modality The | 1994 |
Intraperitoneal cisplatin chemotherapy in ovarian carcinoma patients who are clinically in complete remission.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Female; H | 1992 |
Acute renal failure associated with intraperitoneal cisplatin chemotherapy with systemic thiosulfate protection in ovarian cancer patients.
Topics: Acute Kidney Injury; Cisplatin; Creatinine; Drug Administration Schedule; Female; Humans; Injections | 1991 |
'Two-route chemotherapy' using cisplatin and its neutralizing agent, sodium thiosulfate, for intraperitoneal cancer.
Topics: Adult; Aged; Animals; Antidotes; Breast Neoplasms; Cisplatin; Colonic Neoplasms; Dogs; Female; Human | 1990 |
A phase II trial of intraperitoneal cisplatin and etoposide for primary treatment of ovarian epithelial cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Cisplatin; Drug Evaluation; Etoposide; Fe | 1990 |
[The hypertensive effect induced with angiotensin II and the physiological and pharmacokinetic aspects of two-route chemotherapy using CDDP and STS].
Topics: Angiotensin II; Blood Pressure; Cisplatin; Drug Administration Schedule; Female; Humans; Infusions, | 1990 |
Clinical and pharmacokinetic study of intraperitoneal cisplatin at two dose levels: 100 mg/m2 alone or 200 mg/m2 with i.v. sodium thiosulfate.
Topics: Adenocarcinoma; Antidotes; Cisplatin; Colorectal Neoplasms; Dose-Response Relationship, Drug; Drug T | 1989 |
High-dose intracavitary cisplatin with intravenous thiosulfate. Low incidence of serious neurotoxicity.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Ear Diseases; Fe | 1985 |
[The pharmacokinetics and clinical toxicities following intraperitoneal infusion of cis-diamminedichloroplatinum (II) with simultaneous sodium thiosulfate rescue in patients with ovarian cancer].
Topics: Antidotes; Cisplatin; Female; Humans; Ovarian Neoplasms; Thiosulfates | 1988 |
[A case report of advanced ovarian cancer with chronic renal dysfunction treated by CDDP i.p].
Topics: Cisplatin; Drug Administration Schedule; Female; Humans; Injections; Kidney Failure, Chronic; Middle | 1988 |
[Selective intra-arterial administration of CDDP in a malignant ovarian tumor with peculiar ultrastructural findings].
Topics: Adult; Cisplatin; Cystadenocarcinoma; Female; Humans; Infusions, Intra-Arterial; Ovarian Neoplasms; | 1988 |
[Treatment of gynecological cancer with cis-platinum].
Topics: Adenocarcinoma; Cisplatin; Female; Humans; Infusions, Intravenous; Middle Aged; Ovarian Neoplasms; R | 1987 |
[Pharmacokinetics of cisplatinum (CDDP) and sodium thiosulphate (STS) of intraperitoneal two channel chemotherapy (ip TCC) in man and mongrel dogs].
Topics: Adult; Animals; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Dogs; Female; Humans; Inj | 1986 |
[An experimental study of cisplatin and it's antidote, sodium thiosulfate, in ovarian pseudomyxoma implanted into nude mice abdominal cavity].
Topics: Animals; Antidotes; Body Weight; Cisplatin; Cystadenoma; Female; Mice; Mice, Nude; Neoplasm Transpla | 1986 |
Hypomagnesemia following high-dose intracavitary cisplatin with systemically administered sodium thiosulfate.
Topics: Adult; Aged; Carcinoma; Cisplatin; Dose-Response Relationship, Drug; Female; Humans; Kidney Diseases | 1986 |
Intraperitoneal chemotherapy for advanced ovarian cancer.
Topics: Altretamine; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Cyclophosphamide; Doxorubici | 1985 |
Experimental and clinical results with intraperitoneal cisplatin.
Topics: Antineoplastic Combined Chemotherapy Protocols; Catheterization; Catheters, Indwelling; Cisplatin; F | 1985 |
Intraperitoneal chemotherapy in the management of ovarian cancer.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Catheters, Indwelling; Cispla | 1985 |
Nephrotoxicity of high-dose intracavitary cisplatin with intravenous thiosulfate protection.
Topics: Acute Kidney Injury; Adult; Aged; Cisplatin; Creatinine; Female; Humans; Injections; Injections, Int | 1985 |